Dr. William Williams reports

BRIACELL ENGAGES CONSULTING AND BRANDING FIRMS TO SUPPORT COMMERCIAL AND MARKET ACCESS EVALUATION OF BRIA-IMT

Briacell Therapeutics Corp. has engaged Charles River Associates and Kaleio Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.

Bria-IMT is currently being evaluated in Briacell's continuing pivotal phase 3 study in metastatic breast cancer and is not a commercially approved therapy. These engagements represent a prudent commercial readiness step as Briacell continues to evaluate Bria-IMT, and prepares for potential future commercialization planning and strategic discussions, subject to successful clinical development and applicable regulatory approvals.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.